Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FASgen has been awarded a $500,000 grant from the US National Institutes of Health for completion of the final preclinical safety and animal efficacy work in support of the investigational new drug application for FAS20013 in MDR-TB.
Subscribe to our email newsletter
At the same time, the company has secured a $2 million investment from a private investor to support the MDR-TB (multiple drug-resistant tuberculosis) drug development and clinical trial program.
Preparation of the investigational new drug (IND) application is well underway and submission is planned for later this summer. Phase I trials have been organized at several prospective centers both in and out of the US.
“We look forward to starting clinical trials to confirm in human trials the remarkable success the compound has demonstrated in the various in vivo models,” said Dr Albert Owens, FASgen’s president and founder.”FAS20013 is the first new therapeutic agent for the treatment of TB and MDR-TB to have demonstrated this level of potency and efficacy in the last 45 years.”
FASgen also announced that with MDR-TB listed by the US Department of Homeland Security (DHS) as a potential biological warfare threat, the company has submitted appropriate materials in support of funding to make the product available for the treatment of MDR-TB under the biodefense programs sponsored by the DHS.